IL274943B2 - Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases - Google Patents

Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases

Info

Publication number
IL274943B2
IL274943B2 IL274943A IL27494320A IL274943B2 IL 274943 B2 IL274943 B2 IL 274943B2 IL 274943 A IL274943 A IL 274943A IL 27494320 A IL27494320 A IL 27494320A IL 274943 B2 IL274943 B2 IL 274943B2
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
acceptable salt
aprocitentan
inhibitor
sglt
Prior art date
Application number
IL274943A
Other languages
English (en)
Hebrew (he)
Other versions
IL274943A (en
IL274943B1 (en
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64606962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL274943(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of IL274943A publication Critical patent/IL274943A/en
Publication of IL274943B1 publication Critical patent/IL274943B1/en
Publication of IL274943B2 publication Critical patent/IL274943B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL274943A 2017-11-30 2018-11-29 Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases IL274943B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017081050 2017-11-30
PCT/EP2018/082947 WO2019106066A1 (en) 2017-11-30 2018-11-29 Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases

Publications (3)

Publication Number Publication Date
IL274943A IL274943A (en) 2020-07-30
IL274943B1 IL274943B1 (en) 2024-12-01
IL274943B2 true IL274943B2 (en) 2025-04-01

Family

ID=64606962

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274943A IL274943B2 (en) 2017-11-30 2018-11-29 Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases

Country Status (29)

Country Link
US (2) US12144811B2 (https=)
EP (1) EP3716979B1 (https=)
JP (2) JP7404235B2 (https=)
KR (2) KR20260037123A (https=)
CN (1) CN111405899B (https=)
AU (1) AU2018376263B2 (https=)
BR (1) BR112020010831A2 (https=)
CA (1) CA3083327A1 (https=)
CL (1) CL2020001394A1 (https=)
DK (1) DK3716979T3 (https=)
EA (1) EA202091324A1 (https=)
ES (1) ES3035734T3 (https=)
FI (1) FI3716979T3 (https=)
HR (1) HRP20250732T1 (https=)
HU (1) HUE071739T2 (https=)
IL (1) IL274943B2 (https=)
LT (1) LT3716979T (https=)
MA (1) MA51203A (https=)
MX (1) MX2020005543A (https=)
MY (1) MY210547A (https=)
PH (1) PH12020550745A1 (https=)
PL (1) PL3716979T3 (https=)
PT (1) PT3716979T (https=)
RS (1) RS66980B1 (https=)
SG (1) SG11202004862XA (https=)
SI (1) SI3716979T1 (https=)
TW (1) TWI809009B (https=)
UA (1) UA127083C2 (https=)
WO (1) WO2019106066A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102568472B1 (ko) 2017-02-27 2023-08-18 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
US11723929B2 (en) 2017-06-13 2023-08-15 The Regents Of The University Of California Methods of improving cell-based therapy
AU2020378025A1 (en) * 2019-11-07 2022-06-23 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Aprocitentan, preparation method therefor and use thereof
WO2021092341A1 (en) * 2019-11-07 2021-05-14 Increvet, Inc. Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals
WO2021105164A1 (en) * 2019-11-26 2021-06-03 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary vascular disease and/or cardiac dysfunction in fontan-palliated patients
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
CN115803028A (zh) * 2020-07-10 2023-03-14 阿斯利康(瑞典)有限公司 用于治疗慢性肾病的齐泊腾坦和达格列净的组合
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
AU2021202643B2 (en) * 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
CN114644595A (zh) * 2020-12-19 2022-06-21 普济生物科技（台州）有限公司 阿普昔腾坦的无定型态、其药物组合物和用途
MX2023013662A (es) * 2021-09-02 2024-01-08 Daewoong Therapeutics Inc Composicion farmaceutica para prevenir o tratar una enfermedad ocular diabetica que comprende el inhibidor de sglt-2.
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
AU2023276826A1 (en) 2022-05-22 2025-01-09 Idorsia Pharmaceuticals Ltd Aprocitentan for the treatment of hypertension
US20250340520A1 (en) 2022-05-25 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide
JP2025537256A (ja) * 2022-11-10 2025-11-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンジオポエチン様３（ａｎｇｐｔｌ３）阻害剤と溶質担体ファミリー５メンバー２（ｓｌｃ５ａ２）阻害剤の組み合わせによる腎疾患の治療
EP4640213A1 (en) * 2022-12-20 2025-10-29 THPharm Corp. Oral pharmaceutical preparation comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker
WO2025089933A1 (ko) * 2023-10-24 2025-05-01 주식회사 레드엔비아 Sglt-2 저해제 및 dpp-4 저해제를 포함하는 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제
WO2025261457A1 (zh) * 2024-06-21 2025-12-26 深圳信立泰药业股份有限公司 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364958A1 (en) * 2001-02-27 2003-11-26 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
WO2009024906A1 (en) * 2007-08-17 2009-02-26 Actelion Pharmaceuticals Ltd 4-pyrimidinesulfamide derivative
WO2014161918A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Therapeutic uses of empagliflozin
US20170145000A1 (en) * 2014-03-19 2017-05-25 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
WO2018153513A1 (en) * 2017-02-27 2018-08-30 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
HU229403B1 (en) 2000-12-18 2013-12-30 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
PL209375B1 (pl) 2000-12-28 2011-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
EP1724277A4 (en) 2004-03-04 2012-05-02 Kissei Pharmaceutical ACCOLE HETEROCYCLIC DERIVATIVE, DRUG-CONTAINING COMPOSITION THEREOF, AND THE USE THEREOF
ATE557013T1 (de) 2004-03-16 2012-05-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US20070196510A1 (en) 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
US20070293552A1 (en) 2006-06-15 2007-12-20 Gorczynski Richard J Antihypertensive therapy method
PE20080991A1 (es) 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
MY155418A (en) 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
JP2012528170A (ja) 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
FI4000608T3 (fi) * 2013-04-18 2026-01-21 Boehringer Ingelheim Int Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä
MX2016010011A (es) 2014-01-31 2016-10-07 Janssen Pharmaceutica Nv Metodos para tratar y prevenir trastornos renales y trastornos del higado graso.
EP2907811A1 (en) 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
EP3126346B1 (en) * 2014-04-04 2018-07-11 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EP3142661B1 (en) 2014-05-16 2021-10-06 Astrazeneca AB Method for suppressing glucagon secretion of an sglt2 inhibitor
JP2017534634A (ja) 2014-11-07 2017-11-24 アッヴィ・インコーポレイテッド 体液貯留の予測因子を使用してｃｋｄを処置する方法
WO2017064679A1 (en) 2015-10-15 2017-04-20 Lupin Limited Process for the preparation of amorphous canagliflozin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364958A1 (en) * 2001-02-27 2003-11-26 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
WO2009024906A1 (en) * 2007-08-17 2009-02-26 Actelion Pharmaceuticals Ltd 4-pyrimidinesulfamide derivative
WO2014161918A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Therapeutic uses of empagliflozin
US20170145000A1 (en) * 2014-03-19 2017-05-25 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
WO2018153513A1 (en) * 2017-02-27 2018-08-30 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIDDO J.L. HEERSPINK ET AL:, SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS IN THE TREATMENT OF DIABETES MELLITUS : CARDIOVASCULAR AND KIDNEY EFFECTS, POTENTIAL MECHANISMS, AND CLINICAL APPLICATIONS, 28 July 2016 (2016-07-28) *

Also Published As

Publication number Publication date
HRP20250732T1 (hr) 2025-08-15
MA51203A (fr) 2020-10-07
SG11202004862XA (en) 2020-06-29
MX2020005543A (es) 2020-08-20
CN111405899A (zh) 2020-07-10
CN111405899B (zh) 2025-05-16
PT3716979T (pt) 2025-07-14
JP7404235B2 (ja) 2023-12-25
KR20260037123A (ko) 2026-03-17
US12144811B2 (en) 2024-11-19
KR20200094187A (ko) 2020-08-06
JP2021504423A (ja) 2021-02-15
EA202091324A1 (ru) 2020-10-05
CA3083327A1 (en) 2019-06-06
US20210169881A1 (en) 2021-06-10
IL274943A (en) 2020-07-30
UA127083C2 (uk) 2023-04-05
TWI809009B (zh) 2023-07-21
LT3716979T (lt) 2025-07-10
CL2020001394A1 (es) 2020-10-16
IL274943B1 (en) 2024-12-01
ES3035734T3 (en) 2025-09-08
MY210547A (en) 2025-09-30
US20250120973A1 (en) 2025-04-17
EP3716979A1 (en) 2020-10-07
TW201924685A (zh) 2019-07-01
AU2018376263B2 (en) 2024-10-31
EP3716979B1 (en) 2025-04-09
JP2024037866A (ja) 2024-03-19
RS66980B1 (sr) 2025-07-31
HUE071739T2 (hu) 2025-09-28
WO2019106066A1 (en) 2019-06-06
FI3716979T3 (fi) 2025-07-08
BR112020010831A2 (pt) 2020-11-10
DK3716979T3 (da) 2025-06-30
PL3716979T3 (pl) 2025-08-04
SI3716979T1 (sl) 2025-08-29
AU2018376263A1 (en) 2020-07-16
PH12020550745A1 (en) 2021-04-26
JP7635355B2 (ja) 2025-02-25

Similar Documents

Publication Publication Date Title
IL274943B2 (en) Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases
EP2419097B1 (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
CA2724133C (en) Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine
CA3053991A1 (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
JP2021504423A5 (https=)
JP2018131450A5 (https=)
WO2012041898A1 (en) Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
TW201105336A (en) Combined medicine of pyrazole derivative and biguanide drug
US20230346817A1 (en) Composition and use of sglt-2 inhibitor and angiotensin receptor blockers
JP2022544297A (ja) リモノイド化合物およびｄｐｐ－４阻害剤を含有する組合せ製品
JP2022507533A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2020536121A5 (https=)
CN114423461B (zh) 组合
CN106236815A (zh) 藤黄提取物在防治糖尿病中的应用
US20110045070A1 (en) Combination therapy
EP4486326A1 (en) Compositions and methods for treatment of idiopathic pulmonary fibrosis
JP2008189679A (ja) ２型糖尿病治療用の併用医薬
Mimi et al. Tuberculosis and chronic renal failure; therapy patterns
WO2024204772A1 (ja) 多系統萎縮症の治療又は進行抑制のための医薬組成物
CN105213398B (zh) 一种治疗糖尿病的药物组合物
JP2017128545A (ja) 併用医薬
CN117243947A (zh) 瑞香素及包含其的组合在制备糖尿病并发症药物中的应用
NZ784949A (en) Ripretinib for treating gastrointestinal stromal tumors
HOANG et al. The Efficacy and Safety of SGLT-2 Inhibitors in Patients With Type 2 Diabetes.
Chaplin et al. DPP‐4 inhibitors: their properties and place in treatment